Clinical Trial Search

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants

Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants

Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants

Primary: Event Free Survival. EFS — 66.0 percentage of participants EFS at 3 yrs3

Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants

Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Primary: Complete Remission — 10 participants

Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability

Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…

Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001

Primary: Event-free Survival — 64.9; 70 percentage of participants

Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants

Primary: Complete Response Rate — 89 percentage of patients

Primary: Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. — 91.6; 90.7 Percentage of…

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Response Rate — 0; 0; 0 participants

Primary: Number of Patients That Experienced DLT During Cycle 1 of Therapy — 3; 3; 5; 3 Participants

Primary: Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported — 26 Participants

Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05

Primary: Number of Patients With Complete Remission — 3 participants

Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability

Primary: Overall Survival at One Year — 19 Participants

Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…

Primary: Number of Participants With a Response — 198; 3; 4 Participants

Primary: Complete Response (CR) Rate — 28 percentage of participants